RxDoctor Payments Data

Kara Dodgens

Optometrist · Easley, SCNPI 1710186572

Payments from drug & device makers

$2,983in general payments, 2019–2025

Across 111 payments — averaging $26.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$652
  • Sun Pharmaceutical Industries Inc.$347
  • Tarsus Pharmaceuticals, Inc.$265
  • Oyster Point Pharma, Inc.$249
  • Bausch & Lomb Americas Inc.$240
  • Sight Sciences, Inc.$220
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,983100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,983 in reported general payments places this provider in the 80th percentile of 653 optometrist providers in South Carolina.

See all optometrist providers in South Carolina

Medicare billing

Part B allowed, 2024
$59,395
Medicare patients
369
Services billed
1,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine64$75,166
XiidraLifitegrast29$39,788
CequaCyclosporine30$24,503
Cyclosporine38$22,249
MieboPerfluorohexyloctane/Pf20$18,545
TyrvayaVarenicline Tartrate24$16,393
Lotemax SmLoteprednol Etabonate15$3,743
Latanoprost76$759
Prednisolone Acetate17$514
ErythromycinErythromycin Base14$129
Timolol Maleate15$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$79$75,16664 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$240$58,33349 claims
Sun Pharmaceutical Industries Inc.Cequa$347$24,50330 claims
Oyster Point Pharma, Inc.Tyrvaya$249$16,39324 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm$137$3,74315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 653 optometrist providers in South Carolina.

Other optometrist in Easley

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →